Keywords
Anti-NMDAR
Autoimmune encephalitis
Immunotherapy
Case report
Categories
How to Cite
Abstract
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is the most common type of autoimmune encephalitis, whereas anti-glutamic acid decarboxylase 65 (antiGAD65) encephalitis is a rare autoimmune condition. The coexistence of these two conditions has been rarely reported. In this article, we will discuss this rare association through a case report and attempt to determine its main characteristics. We report the case of an 18-year-old male with no medical history, admitted to the medical Intensive Care Unit (ICU) with a decreased level of consciousness, bizarre behavior, and abnormal movements for one week. These symptoms followed the progression of initial signs such as delirium, which had begun two months earlier. Laboratory analysis revealed an inflammatory syndrome with rhabdomyolysis. Cerebral angio-MRI findings were unremarkable. The electroencephalogram (EEG) showed slow, non-reactive activity. Cerebrospinal fluid (CSF) analysis and infectious studies were normal. However, immunological testing using the immunofluorescence technique revealed the presence of anti-NMDAR antibodies in both serum and CSF, as well as anti-GAD65 antibodies in the serum. The positron emission tomography (PET) scan screening for neoplasm was negative. Therapeutically, the patient was treated with anticonvulsants, antipsychotics, intravenous immunoglobulins, corticosteroids, plasma exchanges, cyclophosphamide, and rituximab. Consequently, he demonstrated a remarkable gradual clinical improvement. This case highlights an aspect of autoimmune dysregulation that may lead to atypical and severe clinical presentations. The co-occurrence of anti-NMDAR and anti-GAD65 encephalitis is a rare condition that can lead to severe manifestations. Early diagnosis using a broad antibody panel facilitates timely and appropriate management.
References
1. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Annals of the New York Academy of Sciences ;1338(1):94–114. Available from: https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/nyas.12553
2. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. The Lancet Infectious Diseases. 2010 Dec;10(12):835–44. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147330991070222X
3. Kerstens J, Schreurs MWJ, De Vries JM, Neuteboom RF, Brenner J, Crijnen YS, et al. Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes: A Nationwide Study on Epidemiology and Antibody Testing Performance. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200318. Available from: https://www.neurology.org/doi/10.1212/NXI.0000000000200318
4. Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology. 2015 Nov 3;85(18):1604–13. Available from: https://www.neurology.org/doi/10.1212/WNL.0000000000001940
5. Schubert J, Brämer D, Huttner HB, Gerner ST, Fuhrer H, Melzer N, et al. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm. 2019 Jan];6(1):e514. Available from: https://www.neurology.org/doi/10.1212/NXI.0000000000000514
6. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 2016 Apr;15(4):391–404. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1474442215004019
7. Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):757–68. Available from: https://jnnp.bmj.com/lookup/doi/10.1136/jnnp-2020-325300
8. Dutra LA, Abrantes F, Toso FF, Pedroso JL, Barsottini OGP, Hoftberger R. Autoimmune encephalitis: a review of diagnosis and treatment. Arq Neuro-Psiquiatr. 2018 Jan; 76(1):41–9. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000100041&lng=en&tlng=en
9. Dalmau J, Graus F. Antibody-Mediated Encephalitis. Ropper AH, editor. N Engl J Med. 2018 Mar;378(9):840–51. Available from: http://www.nejm.org/doi/10.1056/NEJMra1708712
10. Rickenbach C, Gericke C. Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases. Front Neurosci. 2022 Jan 20;15:806260. Available from: https://www.frontiersin.org/articles/10.3389/fnins.2021.806260/full
11. Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, et al. Molecular mimicry and autoimmunity. Journal of Autoimmunity. 2018 Dec; 95:100–23. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0896841118305365
12. Patel A, Meng Y, Najjar A, Lado F, Najjar S. Autoimmune Encephalitis: A Physician’s Guide to the Clinical Spectrum Diagnosis and Management. Brain Sciences. 2022 Aug 25;12(9):1130. Available from: https://www.mdpi.com/2076-3425/12/9/1130
13. Gagnon MM, Savard M. Limbic Encephalitis Associated With GAD65 Antibodies: Brief Review of the Relevant literature. Can J Neurol Sci. 2016 Jul;43(4):486–93. Available from: https://www.cambridge.org/core/product/identifier/S0317167116000135/type/journal_article
14. Titulaer MJ, Höftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, et al. Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitis. Annals of Neurology. 2014 Mar;75(3):411–28. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ana.24117
15. McEntire C, Manzano G, Linnoila J. Co-Occurring NMDA-Receptor and Anti-GAD65 Antibodies in the CSF of a Patient With Encephalitis: Case Report. Neurology. 2022 Dec 5;99(23_Supplement_2). Available from: https://www.neurology.org/doi/10.1212/01.wnl.0000903592.90530.d1
16. Kammeyer R, Piquet AL. Multiple co-existing antibodies in autoimmune encephalitis: A case and literature review. Journal of Neuroimmunology. 2019 Dec ;337:577084. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0165572819303170
17. Oropeza IG, Fuentes I, Medina SM. Early Relapse in Anti-GAD65 and Anti-NMDA Co-expression Associated Autoimmune Encephalitis: A Case Report. Neurology. 2024 Oct 8;103(7_Supplement_1). Available from: https://www.neurology.org/doi/10.1212/01.wnl.0001051444.24716.31
18. Valadez-Calderon J, Ordinola Navarro A, Rodriguez-Chavez E, Vera-Lastra O. Co-expression of anti-NMDAR and anti-GAD65 antibodies. A case of autoimmune encephalitis in a post-COVID-19 patient. Neurología. 2022 Jul;37(6):503–4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0213485321002462
19. Gaspard N. How Much GAD65 Do You Have? High Levels of GAD65 Antibodies in Autoimmune Encephalitis. Epilepsy Curr. 2020 Aug 25;20(5):267–70. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653657/
20. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet Neurology. 2013 Feb;12(2):157–65. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1474442212703101
21. Qiu Z, Xu F, Zhang M, Yang X, Han Y, Li D, et al. Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China. CNS Neurosci Ther. 2025 Feb;31(2):e70237. Available from: https://onlinelibrary.wiley.com/doi/10.1111/cns.70237
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 ASIDE Internal Medicine